| abstract |
The present invention provides the use of IFN-beta, an agent that increases the expression of IFN-beta, or a polynucleotide which is capable of expressing IFN-beta or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. |